Continuous Glucose Monitors Help Reduce A1c in Patients with Diabetes
Drug Topics
JULY 1, 2024
Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.
Drug Topics
JULY 1, 2024
Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.
Pharmacy Times
JULY 1, 2024
Ustekinumab-ttwe (Pyzchiva; Sandoz) is approved for all indications of Stelara.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 1, 2024
Drug Topics sat down with Sandra Canally, RN, founder and CEO of The Compliance Team, and Kara Benson, PharmD, long-term care director of Lewis Drug Inc, to discuss the future of LTC pharmacy.
STAT
JULY 1, 2024
Bird flu snapshot: This is the latest installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. When pathologist Thijs Kuiken looks at what’s happening in the U.S. response to the H5N1 bird flu outbreak in dairy cows, he’s reminded of a difficult period in the Netherlands, where he lives, back in the late aughts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
JULY 1, 2024
Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday. | Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday.
STAT
JULY 1, 2024
For 15 years, a formidable CEO-CFO duo often called “the two Tonys” ushered their St. Louis-based health system through a period of explosive growth, adding hospital after hospital until it became one of the country’s biggest health systems. The year after former CEO Anthony Tersigni and former finance chief Anthony Speranzo stepped down, their sprawling empire of roughly 140 hospitals underwent the ultimate stress test: the Covid-19 pandemic.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JULY 1, 2024
There has been much handwringing about how difficult it is for Americans with mental health issues to see a psychiatrist. Failures in the health insurance market are often blamed for the problem. As a new class of psychiatry residents begins work in hospitals across the country this week, I see an additional cause: the lack of commitment to honor the subsidies that made it possible for psychiatrists to enter the profession.
Pharmacy Times
JULY 1, 2024
Perinatal depression increases the risk of cardiovascular disease in women.
STAT
JULY 1, 2024
A novel surgical technique could dramatically improve walking for people with below-the-knee amputations and help them better control their prosthetics. A study published Monday in Nature Medicine showed that trial participants who received the procedure could walk faster, were more stable on uneven terrain, and had an increased spatial awareness, or proprioception, in their residual limb.
Pharmacy Times
JULY 1, 2024
Additionally, birth weight was higher in babies born to mothers who were prescribed glucagon-like peptide-1 (GLP-1) medications either 90 days prior to pregnancy or during the first trimester.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JULY 1, 2024
The microbiome has immense power to shape health outcomes. The bacteria that take up residence in the human body, including the gut, have been shown to impact health and disease, including neurodegenerative disorders. Medical research is invested in finding ways to reconstruct healthy microbiomes to help cure some of those ills. But like many fields in science , microbiome research is suffering from a reproducibility crisis.
Fierce Healthcare
JULY 1, 2024
OptumRx will pay $20 million to resolve claims the company violated the Controlled Substances Act by improperly filling certain opioid prescriptions, the Department of Justice recently announced.
STAT
JULY 1, 2024
The Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to remove approximately two dozen patents for asthma and COPD inhalers from a key federal registry. The agency sent a civil investigative demand requiring Teva to provide information related to the patents listed in the so-called Orange Book, which is maintained by the Food and Drug Administration.
Pharmaceutical Technology
JULY 1, 2024
On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JULY 1, 2024
My dad, Randy, a 72-year-old retired sales manager, started to gain weight after grad school, and it didn’t let up until he was middle-aged. He’s now living with high blood pressure and high cholesterol. His cardiologist has told him, “You know, if you lost 15 pounds, you could get off your blood pressure medicine.
pharmaphorum
JULY 1, 2024
Informed patient consent is crucial for the success of clinical trials. Learn about the importance of consent in clinical trials and how it impacts the outcomes.
Fierce Pharma
JULY 1, 2024
GSK scratched another Zantac lawsuit off the list with a confidential settlement in Illinois as it continues to work through the mountain of personal injury litigation related to the heartburn pill | Following a win and a separate dismissal in Illinois, GSK agreed to a confidential settlement to resolve prostate cancer claims put forward by plaintiff Martin Gross.
pharmaphorum
JULY 1, 2024
ASCO 2024 conference highlights the latest advancements in oncology, emphasising the art and science behind enhanced cancer care. Stay updated on the latest research, treatments, and innovations in the field of oncology.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JULY 1, 2024
Welcome to Fierce Pharma's regulatory tracker for the second half of 2024. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
pharmaphorum
JULY 1, 2024
France's HAS agrees to fund treatment with Carthera's ultrasound device for French subjects enrolled in a glioblastoma trial.
STAT
JULY 1, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the familiar routine of online meetings, calls, and deadlines has predictably returned. But you know, the world — such as it is — continues to spin. So what can you do but try to give it a nudge in a better direction.
pharmaphorum
JULY 1, 2024
AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The drugmaker said this morning that an application for sipavibart (AZD3152) has been accepted for review by the EMA as PrEP for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.
European Pharmaceutical Review
JULY 1, 2024
At its recent June meeting, the EMA’s human medicines committee (CHMP) recommended 10 medicines for approval. Recommendations for regulatory approval The committee saw a need to give a marketing authorisation to Balversa (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma. In its meeting, the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions.
pharmaphorum
JULY 1, 2024
Explore the reasons behind the drop in the UK's healthcare spending and analyse whether this trend is sustainable for the NHS in the long term. Learn about the potential impacts and future implications.
The Checkup by Singlecare
JULY 1, 2024
Prednisone is a glucocorticoid, often called a steroid. It is a prescription medication that manages conditions that need to suppress inflammation. It treats a wide variety of conditions, including asthma, allergic reactions, rheumatoid arthritis, eye or vision problems, autoimmune diseases, gastrointestinal issues such as inflammatory bowel disease, hormone disorders, skin diseases, soft tissue diseases, blood disorders, cancer, and other medical conditions.
pharmaphorum
JULY 1, 2024
An interview with Chris Moore about Veeva R&D and Quality, looking ahead to 2024. Explore insights and predictions for the industry from this expert perspective.
Drug Topics
JULY 1, 2024
Jeremy Cundiff, PharmD, co-owner of Professional Pharmacy Group, joined Drug Topics to discuss Return Solutions and the company’s Rx Returns process.
pharmaphorum
JULY 1, 2024
NeuroSense Tx reports 12-month data with its amyotrophic lateral sclerosis therapy PrimeC, including a 43% improvement in survival
Fierce Pharma
JULY 1, 2024
In yet another legal development surrounding counterfeit HIV drugs, a Florida court has handed down an indictment for the owners of a wholesale distributor that allegedly bought and redistribu | The wholesaler Safe Chain allegedly purchased $90 million of misbranded, diverted and adulterated HIV meds, according to U.S. authorities. The indictment of the company's three owners follows separate lawsuits from Gilead and Johnson & Johnson.
pharmaphorum
JULY 1, 2024
Bristol-Myers Squibb ends $3.
Fierce Pharma
JULY 1, 2024
Less than three weeks after a group of cancer victims filed a motion against Johnson & Johnson attempting to block the company’s latest bankruptcy plan—which comes with a $6.5 billion class-act | Less than three weeks after a group of cancer victims filed a motion attempting to block Johnson & Johnson's latest talc litigation bankruptcy plan—which comes with a $6.5 billion class-action settlement offer—a New Jersey federal court has quashed the effort.
pharmaphorum
JULY 1, 2024
Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright for $1 billion.Radionetics is working on small-molecule drugs that target G protein-coupled receptors (GPCRs), a fertile source of drug targets for the pharma industry and the target of around a third of all marketed drugs but according to the company is a “largely unexplored” class for radiopharma.
The Checkup by Singlecare
JULY 1, 2024
Quercetin is a flavonoid, a compound that gives plants—including fruits, vegetables, herbs, and flowers—their color. It’s found in many common foods and drinks, such as citrus fruit, apples, onions, buckwheat, cherries, berries, broccoli, red wine, green tea, parsley, sage, dill, and coriander. It’s also available as a supplement. If you’ve noticed it in grocery and drug store aisles recently, it may be because this dietary antioxidant is becoming more popular.
Let's personalize your content